NCT03330561: PRS-343 in HER2-Positive Solid Tumors

NCT03330561
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Known uncontrolled central nervous system (CNS) metastases – see trial for details
https://ClinicalTrials.gov/show/NCT03330561

Comments are closed.

Up ↑